{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed+and%2For+Refractory+Diffuse+Large+B-Cell+Lymphoma+%28DLBCL%29", "query": { "condition": "Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 105, "total_pages": 11, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed+and%2For+Refractory+Diffuse+Large+B-Cell+Lymphoma+%28DLBCL%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-11T06:22:43.520Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06508658", "title": "A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diffuse Large B-Cell Lymphoma" ], "interventions": [ { "name": "Epcoritamab", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genmab", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 379, "start_date": "2024-08-13", "completion_date": "2028-03", "has_results": false, "last_update_posted_date": "2026-04-08", "last_synced_at": "2026-06-11T06:22:43.520Z", "location_count": 19, "location_summary": "Duarte, California • Los Angeles, California • Palm Springs, California + 15 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palm Springs", "state": "California" }, { "city": "Golden", "state": "Colorado" }, { "city": "Newnan", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06508658" }, { "nct_id": "NCT02142049", "title": "Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Diffuse Large B Cell Lymphoma Relapsed", "Diffuse Large B Cell Lymphoma Refractory" ], "interventions": [ { "name": "Ibrutinib", "type": "DRUG" }, { "name": "DA-EPOCH-R", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pharmacyclics LLC.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2014-05", "completion_date": "2017-08", "has_results": true, "last_update_posted_date": "2019-02-05", "last_synced_at": "2026-06-11T06:22:43.520Z", "location_count": 10, "location_summary": "Duarte, California • Los Angeles, California • Orange, California + 7 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02142049" }, { "nct_id": "NCT05319028", "title": "Study of Mivavotinib (CB-659) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-GCB/ABC Diffuse Large B-Cell Lymphoma", "With and Without MyD88 and/or CD79B Mutations" ], "interventions": [ { "name": "Mivavotinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Calithera Biosciences, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 2, "start_date": "2022-06-23", "completion_date": "2023-02-24", "has_results": false, "last_update_posted_date": "2023-04-04", "last_synced_at": "2026-06-11T06:22:43.520Z", "location_count": 7, "location_summary": "Evanston, Illinois • Detroit, Michigan • Cleveland, Ohio + 4 more", "locations": [ { "city": "Evanston", "state": "Illinois" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Toledo", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05319028" }, { "nct_id": "NCT04404283", "title": "Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diffuse Large B-cell Lymphoma" ], "interventions": [ { "name": "Brentuximab vedotin", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Seagen, a wholly owned subsidiary of Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 239, "start_date": "2020-08-20", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-04-20", "last_synced_at": "2026-06-11T06:22:43.520Z", "location_count": 49, "location_summary": "Birmingham, Alabama • Sacramento, California • Bonita Springs, Florida + 31 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Sacramento", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Bonita Springs", "state": "Florida" }, { "city": "Bradenton", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04404283" }, { "nct_id": "NCT06768905", "title": "IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCL", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non Hodgkin Lymphoma", "Diffuse Large B Cell Lymphoma" ], "interventions": [ { "name": "Iomab-B", "type": "DRUG" }, { "name": "CAR-T cell", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2025-04-25", "completion_date": "2030-05", "has_results": false, "last_update_posted_date": "2026-05-08", "last_synced_at": "2026-06-11T06:22:43.520Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06768905" }, { "nct_id": "NCT00655837", "title": "Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma, Large B-Cell, Diffuse", "Lymphoma, Non-Hodgkin" ], "interventions": [ { "name": "SGN-40", "type": "DRUG" }, { "name": "rituximab", "type": "DRUG" }, { "name": "gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2008-04", "completion_date": "2010-02", "has_results": false, "last_update_posted_date": "2014-12-18", "last_synced_at": "2026-06-11T06:22:43.520Z", "location_count": 9, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Aurora, Colorado + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Park Ridge", "state": "Illinois" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT00655837" }, { "nct_id": "NCT05512390", "title": "A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diffuse Large B-Cell Lymphoma", "Chronic Lymphocytic Leukemia", "Follicular Lymphoma" ], "interventions": [ { "name": "ABBV-319", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 154, "start_date": "2023-04-26", "completion_date": "2027-02", "has_results": false, "last_update_posted_date": "2026-01-16", "last_synced_at": "2026-06-11T06:22:43.520Z", "location_count": 8, "location_summary": "Tucson, Arizona • Miami, Florida • Minneapolis, Minnesota + 5 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Miami", "state": "Florida" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05512390" }, { "nct_id": "NCT04697160", "title": "Observational Retrospective Cohort Study of Systemic Therapies for R/R DLBCL", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Diffuse Large B Cell Lymphoma" ], "interventions": [], "intervention_types": [], "sponsor": "MorphoSys AG", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3573, "start_date": "2020-04-01", "completion_date": "2021-05-07", "has_results": false, "last_update_posted_date": "2021-10-20", "last_synced_at": "2026-06-11T06:22:43.520Z", "location_count": 22, "location_summary": "Scottsdale, Arizona • Clovis, California • Los Angeles, California + 18 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Clovis", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Torrance", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04697160" }, { "nct_id": "NCT03888105", "title": "A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "B-cell Non-Hodgkin Lymphoma (B-NHL)" ], "interventions": [ { "name": "Odronextamab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 515, "start_date": "2019-11-13", "completion_date": "2028-12-15", "has_results": false, "last_update_posted_date": "2025-10-15", "last_synced_at": "2026-06-11T06:22:43.520Z", "location_count": 13, "location_summary": "Chicago, Illinois • Iowa City, Iowa • Louisville, Kentucky + 9 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03888105" }, { "nct_id": "NCT01014208", "title": "Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lymphoma, Large-Cell, Diffuse" ], "interventions": [ { "name": "OFATUMUMAB + DHAP", "type": "DRUG" }, { "name": "RITUXIMAB + DHAP", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 447, "start_date": "2010-03", "completion_date": "2014-11", "has_results": true, "last_update_posted_date": "2015-08-07", "last_synced_at": "2026-06-11T06:22:43.520Z", "location_count": 16, "location_summary": "Sacramento, California • New Haven, Connecticut • Chicago, Illinois + 12 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Westwood", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01014208" } ] }